High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy (Q36911254)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 April 2013

Language	Label	Description	Also known as
English	High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy	scientific article published on 3 April 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Dongyi He

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Fengmin Bai

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Shu Zhang

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Ting Jiang

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Jie Shen

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Qi Zhu

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Tao Yue

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Lingyun Shao

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Yan Gao

9

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Yun Feng

10

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Xinhua Weng

11

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Hejian Zou

12

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Ying Zhang

13

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Wenhong Zhang

14

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

publication date

3 April 2013

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Clinical and Vaccine Immunology

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

20

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

842-847

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Evaluation of Gamma Interferon Release Assays Using Mycobacterium tuberculosis Antigens for Diagnosis of Latent and Active Tuberculosis in Mycobacterium bovis BCG-Vaccinated Populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-gamma release assay among HIV-infected individuals in BCG-vaccinated area

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Anakinra for rheumatoid arthritis: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

29 September 2017

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

4 September 2018

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

4 September 2018

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675964

4 December 2018

Granulomatous infections due to tumor necrosis factor blockade: correction

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/CVI.00049-13

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36911254&oldid=2088584900"